Publication date: 19th October 2022
In this case study module, Roberto Hegg discusses the current treatment guidelines and emerging therapies for HR+/HER2- early breast cancer, and the most appropriate management approaches based on the identified recurrence risk factors, with reference to the treatment of a 43-year old HR+/HER2- early breast cancer patient.
Learning objectives
After completing this activity, you will be able to:
- Describe the most appropriate first-line treatment options based on risk of recurrence
- Explain the most appropriate subsequent-line treatment options based on residual risk
Accreditation
Expiration date: 19 October 2023
Estimated time to complete: 15 minutes
When you have completed this activity you will be asked to fill in a short evaluation survey. Your feedback helps us to give you the best learning experience.
In support of improving patient care, this activity is accredited by North American Center for Continuing Medical Education (NACCME) for 0.25 AMA PRA Category 1 Credit(s)™. Should you wish to claim credits for this activity, please select “yes” in the evaluation survey when directed and download your certificate. Should you simply wish to provide us with valuable feedback, please select “no” when directed and submit your feedback.
Sign up for new content alerts
Enter your email address below and we'll contact you as soon as new content is launched!
